oxazoles has been researched along with thiophenes in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (13.68) | 18.7374 |
| 1990's | 2 (2.11) | 18.2507 |
| 2000's | 10 (10.53) | 29.6817 |
| 2010's | 49 (51.58) | 24.3611 |
| 2020's | 21 (22.11) | 2.80 |
| Authors | Studies |
|---|---|
| Müller, HK; Schuart, J | 1 |
| Günther, O; Hartke, K | 1 |
| Le-Hong, N; Martin, O; Perret, F; Tronchet, JM; Zumwald, JB | 1 |
| Fukumi, H; Sakamoto, T; Sugiyama, M; Tabata, K | 1 |
| Baumann, K; Binder, D; Holzer, W; Noe, CR | 2 |
| Allen, SD; Mitchell, JT; Mullen, GB; St Georgiev, V | 1 |
| Atsumi, T; Horiuchi, Y; Kinoshita, Y; Nishida, K; Shibata, K | 1 |
| Baker, AD; Betteridge, D; Kemp, NR; Kirby, RE | 1 |
| Dunoff, RY; Graboyes, H; Jaffe, G; Karash, CB; Pachter, IJ; Snader, K; Weinstock, J | 1 |
| Breddin, HK; Pauliks, V; Weichert, W | 1 |
| Jarrott, B; Louis, WJ; Summers, RJ | 1 |
| Engel, J; Sheldrick, WS; von Schlichtegroll, A | 1 |
| Janssen, BJ; Oosting, J; Struyker-Boudier, HA; Tyssen, CM | 1 |
| Broom, NJ; Elder, JS; Hannan, PC; O'Hanlon, PJ; Pons, JE; Walker, G; Wilson, J; Woodall, P | 1 |
| Inoue, Y; Ishikawa, H; Katsura, Y; Matsumoto, Y; Morinaga, C; Nishino, S; Sakane, K; Takasugi, H | 1 |
| Dalvie, DK; Kalgutkar, AS; Khojasteh-Bakht, SC; O'Donnell, JP; Obach, RS | 1 |
| Adler, M; Biancalana, S; Kochanny, MJ; Light, DR; Rumennik, G; Whitlow, M; Ye, B | 1 |
| Alsaïdi, A; Bureau, R; Collot, V; Dallemagne, P; Khanh, LP; Paillet, M; Rault, S; Varlet, I | 1 |
| Dallemagne, P; Omran, Z; Rault, S | 1 |
| Doucet, H; Roger, J | 1 |
| Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D | 1 |
| Charbonnel, B | 1 |
| Chognot, C; Henry, RR; Herz, M; Lincoff, AM; Mudaliar, S; Rabbia, M | 1 |
| Bardsley, MR; Farrugia, G; Gibbons, SJ; Lei, S; Ordog, T; Roeder, JL; Stanich, JE; Strege, PR; Tharayil, VS; Wouters, MM | 1 |
| Castilla, J; Castillón, S; Díaz, Y; Marín, I; Matheu, MI | 1 |
| Banken, L; Jamois, C; Liogier D'ardhuy, X; Sanwald-Ducray, P | 1 |
| Cavender, MA; Lincoff, AM | 1 |
| Gaspari, F; Herz, M; Perico, N; Rabbia, M; Urbanowska, T; Viberti, G; Wieczorek Kirk, D | 1 |
| Lecka-Czernik, B | 1 |
| Foley-Comer, AJ; Jordan, P; Russell-Yarde, F; Young, AM | 1 |
| Bénardeau, A; Hansen, BC; Meyer, M; Mizrahi, J; Sebokova, E; Tigno, XT | 1 |
| Basu, S; Giri, S; Gite, A; Godha, A; Goswami, A; Jain, M; Patel, P; Pingali, H; Raval, P; Raval, S; Shah, M; Suthar, D | 1 |
| Davis, SN; Uhl, L; Younk, LM | 1 |
| Bentley, D; Jordan, P; Ruf, T; Russell-Yarde, F; Sturm, S | 1 |
| Funk, C; Paehler, A; Ruf, T; Seiberling, M; Sturm, S; Weick, I | 1 |
| Wilding, JP | 1 |
| Benz, J; Dietz, M; Grether, U; Hartman, P; Kuhn, B; Maerki, HP; Mohr, P; Ruf, A; Wright, MB | 1 |
| Blander, G; Bobadilla, M; Catlett, NL; Deehan, R; Edgar, A; Elliston, KO; Haefliger, C; Ladd, W; Maerz-Weiss, P; Mizrahi, J; Steiner, G; Wong, B; Wright, MB | 1 |
| Atzpodien, EA; Bénardeau, A; Funk, JM; Meyer, M; Mizrahi, J; Sebokova, E; Uhles, S; Verry, P; Winter, M; Wright, MB | 1 |
| Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS | 1 |
| Beall, HD; Bibby, JM; Hassani, M; Moody, CJ; Newsome, JJ; Swann, E | 1 |
| Adedeji, AO; Jonsson, C; Sarafianos, SG; Severson, W; Singh, K; Weiss, SR | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Banken, L; Jamois, C; Sanwald-Ducray, P | 1 |
| Böhm, M; Gensch, C; Laufs, U; Pavlickova, V; Pöss, J; Schirmer, SH; Werner, CM; Wright, MB | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Svensson, A; Tardif, JC; Volz, D; Wedel, H; Weichert, A | 1 |
| Chen, Z; Li, M; Li, Z; Shi, L; Shi, Q; Su, S; Tang, C; Wang, H; Wu, F; Xiao, H | 1 |
| Jiang, Y; Kato, K; Kusakabe, T; Takahashi, K | 1 |
| Mearns, BM | 1 |
| Hanefeld, M; Herz, M; Lincoff, AM; Malmberg, K; Meyer-Reigner, S; Mudie, N; Ruilope, L; Viberti, G; Wieczorek Kirk, D | 1 |
| Futamura, T; Hashimoto, K; Ishima, T; Kikuchi, T; Ohgi, Y; Yoshimi, N | 1 |
| Andjelkovic, M; Buse, JB; Durrwell, L; El Azzouzi, B; Henry, RR; Herz, M; Jaekel, K; Mingrino, R; Wu, H | 1 |
| Boyce, JA; Laidlaw, TM | 1 |
| Bengus, M; Califf, R; Ditmarsch, M; Erdmann, E; Gerstein, HC; Malmberg, K; Ruilope, L; Schwartz, GG; Svensson, A; Volz, D; Wedel, H | 1 |
| Varadharajan, V | 1 |
| Jin, X; Lei, C; Zhou, JS | 1 |
| Andjelkovic, M; Fischer, A; Gastaldelli, A; Heise, T; Herz, M; Nosek, L; Stirban, AO | 1 |
| Baradaran, B; Majidinia, M; Rameshknia, V; Samadi, N; Shafiei-Irannejad, V; Targhaze, N; Yousefi, B; Zarghami, N | 1 |
| Bajaj, M; Birnbaum, Y; Chen, H; Nanhwan, MK; Qian, J; Ye, Y | 1 |
| Calabriso, N; Carluccio, MA; De Caterina, R; Massaro, M; Pellegrino, M; Scoditti, E; Storelli, C; Wabitsch, M; Wright, M | 1 |
| Baillie, TA; Cyrus Khojasteh, S; Dalvie, D; Rietjens, IM | 1 |
| Agarwal, AK; Garg, A; Sankella, S | 1 |
| Bajaj, M; Birnbaum, Y; Chen, H; Chen, Y; Nanhwan, MK; Qian, J; Ye, Y | 1 |
| Atzpodien, EA; Bopst, M | 1 |
| Cosentino, F; Grobbee, DE; Lincoff, AM; Mellbin, L; Morici, N; Nozza, A; Perrone Filardi, P; Ponticelli, C; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC | 1 |
| Cavallini, C; Cosentino, F; Eijkemans, MJ; Ferri, M; Grobbee, DE; Lambers Heerspink, HJ; Lincoff, AM; Malmberg, K; Morici, N; Morocutti, G; Murena, E; Nozza, A; Perrone Filardi, P; Ryden, L; Savonitto, S; Schrieks, IC; Schwartz, GG; Stähli, BE; Tardif, JC; Toyama, T | 1 |
| Alnabulsi, S; Alsalahat, I; Baldwin, AG; Bryce, RA; Freeman, S; Hussein, B; Kadirvel, M; Magwaza, RN; Russo, I; Santina, E; Schwalbe, CH; Stratford, IJ | 1 |
| Buse, JB; Grobbee, DE; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Hou, MC; Hsieh, YC; Huang, CC; Huang, SF; Huang, YH; Lee, KC; Li, TH; Lin, HC; Liu, RS; Tsai, HC; Yang, YY | 1 |
| Boujon, V; Endres, M; Gertz, K; Kronenberg, G; Laufs, U; Uhlemann, R; Wegner, S; Wright, MB | 1 |
| Cong, H; Fan, B; Gu, J; Wang, T; Zhong, W | 1 |
| Grobbee, DE; Heerspink, HJL; Koomen, JV; Lincoff, AM; Nicholls, SJ; Schrieks, IC; Schwartz, GG; Stevens, J; Svensson, A; Wedel, H; Weichert, A | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Giancotti, G; Neyts, J; Pasqualetto, G; Rigo, I; Rocha-Pereira, J; Young, MT | 1 |
| Han, CL; Qu, CZ | 1 |
| Helbig, R; Karadzovska, D; Wiseman, S; Young, L | 1 |
| Finn, DP; Gaspar, JC; Llorente-Berzal, A; Okine, BN; Roche, M | 1 |
| Han, HS; Yasmin, L | 1 |
| Drosatos, K; Kalliora, C | 1 |
| Charnet, P; Charvet, CL; Debierre-Grockiego, F; Dimier-Poisson, I; Dupuy, C; Lamassiaude, N; Neveu, C; Toubate, B | 1 |
| Chappell, K; Karadzovska, D; Nanchen, S; Paarlberg, T; Seewald, W | 1 |
| Helbig, R; Karadzovska, D; Paarlberg, T | 1 |
| Bowman, DD; Crawley, E; Reinemeyer, CR; Snyder, DE; Wallace, K; Wiseman, S | 1 |
| Hayes, B; Snyder, DE; Wiseman, S | 1 |
| Bowman, DD; Crawley, E; Reinemeyer, CR; Snyder, DE; Wiseman, S; Young, LM | 1 |
| Riggs, KL; Wiseman, S | 1 |
| Crawley, E; Snyder, DE; Wallace, K; Wiseman, S; Young, LM | 1 |
| Traversa, D | 1 |
| Forster, S; Snyder, DE; Wiseman, S | 1 |
| Burke, MC; Hedberg, M; Herrin, BH; Jones, L; Kollasch, TM; Locklear, C; Miller, L; Reeves, S; Reif, KE; Ritchie, D; Rumschlag, AJ; Ryan, WG; Smith, V; Sutherland, C; Wenger, MJ | 1 |
| Baba, SN; Ceballos, JC; Corredor-Ortega, C; Gonzalez-Salinas, R; Holdbrook, M; Karpecki, P; Massaro-Corredor, M; Quiroz-Mercado, H; Ramos-Betancourt, N; Yeu, E | 1 |
| Fuatos Gámez, BA; Miranda Contreras, L; Romero Núñez, C; Sánchez Cisneros, JS; Villarreal Villarreal, JP | 1 |
| Cheng, M; Su, X; Sun, N; Sun, Y; Tian, L; Yin, W; Zhang, C; Zhao, D; Zhao, L; Zhao, S; Zheng, Y | 1 |
| Ailiesei, GL; Bendrea, AD; Cianga, I; Cianga, L; Göen Colak, D; Popescu, I | 1 |
9 review(s) available for oxazoles and thiophenes
| Article | Year |
|---|---|
Biotransformation reactions of five-membered aromatic heterocyclic rings.
Topics: Animals; Cytochrome P-450 Enzyme System; Furans; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Indoles; Isoxazoles; Models, Chemical; Molecular Structure; Oxadiazoles; Oxazoles; Pyrazoles; Pyrroles; Tetrazoles; Thiadiazoles; Thiazoles; Thiophenes; Triazoles; Xenobiotics | 2002 |
Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes | 2010 |
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
Topics: Apolipoproteins B; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Fibric Acids; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Triglycerides | 2011 |
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration | 2012 |
Platelets in patients with aspirin-exacerbated respiratory disease.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Clinical Trials as Topic; Eosinophils; Gene Expression; Humans; Leukotrienes; Oxazoles; Piperazines; Platelet Activating Factor; Platelet Activation; Prasugrel Hydrochloride; Receptors, Leukotriene; Thiophenes; Thromboxane A2 | 2015 |
Biotransformation and bioactivation reactions - 2015 literature highlights.
Topics: Acetaminophen; Allylbenzene Derivatives; Aniline Compounds; Animals; Anisoles; Benzbromarone; Biotransformation; Humans; Imidazoles; Niacinamide; Nitroimidazoles; Nitrosamines; Oxazoles; Oxazolidinones; Peroxides; Pyrazines; Pyrazoles; Pyridazines; Pyridines; Pyridones; Pyrimidinones; Thiophenes; Triazoles | 2016 |
Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Lipids; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Thiophenes; Treatment Outcome; Weight Gain | 2020 |
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Signal Transduction; Thiophenes | 2020 |
22 trial(s) available for oxazoles and thiophenes
| Article | Year |
|---|---|
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Topics: Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Least-Squares Analysis; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Safety; Single-Blind Method; Thiazolidinediones; Thiophenes; Treatment Outcome | 2009 |
Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
Topics: Aged; Area Under Curve; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxazoles; Socioeconomic Factors; Thiophenes | 2010 |
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Oxazoles; Prognosis; Renal Insufficiency; Retrospective Studies; Thiophenes; Young Adult | 2011 |
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Topics: Adolescent; Adult; Aged; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thiophenes; Young Adult | 2011 |
No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Topics: Adult; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Oxazoles; PPAR alpha; PPAR gamma; Quinolines; Thiophenes; Time Factors; Young Adult | 2012 |
Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
Topics: Adult; Aged; Carbon Radioisotopes; Humans; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes | 2012 |
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morbidity; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk Factors; Stroke; Thiophenes; Treatment Outcome | 2013 |
The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
Topics: Anticoagulants; Area Under Curve; Cross-Over Studies; Drug Interactions; Factor VII; Humans; Male; Oxazoles; PPAR alpha; PPAR gamma; Prothrombin Time; Stereoisomerism; Thiophenes; Warfarin; Young Adult | 2014 |
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk; Stroke; Survival Analysis; Thiophenes; Treatment Outcome | 2014 |
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kidney; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Renal Insufficiency, Chronic; Therapeutic Equivalency; Thiazolidinediones; Thiophenes | 2014 |
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Thiophenes | 2015 |
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Myalgia; Myocardial Infarction; Myositis; Oxazoles; Peripheral Arterial Disease; PPAR alpha; PPAR gamma; Prediabetic State; Stroke; Thiophenes; Treatment Outcome | 2015 |
Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Fasting; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipid Metabolism; Metabolic Syndrome; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Thiophenes; Treatment Outcome | 2016 |
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Analysis of Variance; Biomarkers; Cause of Death; Comorbidity; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Oxazoles; Patient Discharge; Percutaneous Coronary Intervention; Peroxisome Proliferator-Activated Receptors; Predictive Value of Tests; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Thiophenes | 2017 |
Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Glucose; Chi-Square Distribution; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Revascularization; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome | 2018 |
Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Natriuretic Peptide, Brain; Oxazoles; Peptide Fragments; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Analysis; Thiophenes | 2018 |
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome | 2018 |
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
Topics: Aged; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Female; Heart Disease Risk Factors; Humans; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Risk Factors; Thiophenes | 2020 |
Efficacy of lotilaner (Credelio™) against the adult cat flea, Ctenocephalides felis and flea eggs following oral administration to dogs.
Topics: Administration, Oral; Animals; Ctenocephalides; Dog Diseases; Dogs; Female; Flea Infestations; Insecticides; Male; Ovum; Oxazoles; Thiophenes | 2020 |
Long-term and acute safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio
Topics: Administration, Oral; Animals; Dog Diseases; Dogs; Drug Combinations; Female; Insecticides; Macrolides; Male; Oxazoles; Thiophenes | 2021 |
Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio
Topics: Administration, Oral; Animals; Cohort Studies; Dog Diseases; Dogs; Drug Combinations; Europe; Female; Flea Infestations; Macrolides; Male; Oxazoles; Random Allocation; Tablets; Thiophenes; Tick Infestations | 2021 |
Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial.
Topics: Animals; Blepharitis; Eyelashes; Humans; Mite Infestations; Mites; Ophthalmic Solutions; Oxazoles; Thiophenes | 2022 |
64 other study(ies) available for oxazoles and thiophenes
| Article | Year |
|---|---|
[2-Aminooxazoles and 2-iminooxazolines. 5. Studies on aromatic substitution of thiophene in 2-imino-5-thiene-(2)-yloxazolines].
Topics: Amines; Chemical Phenomena; Chemistry; Imines; Oxazoles; Thiophenes | 1975 |
[Heterocyclic o-amino-phosphonic esters (author's transl)].
Topics: Heterocyclic Compounds; Organophosphonates; Oxazoles; Pyrimidines; Thiazoles; Thiophenes | 1975 |
[C-glycoside derivatives. XXVI. New ways of approach to thiophene and isoxazole C-nucleosides].
Topics: Nucleosides; Oxazoles; Thiophenes | 1975 |
Condensed thienopyrimidines. IV. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidine derivatives.
Topics: Animals; Anti-Ulcer Agents; Chemical Phenomena; Chemistry; Gastric Mucosa; Male; Oxazoles; Pyrimidines; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Thiophenes | 1989 |
[Thiophene as a structural element in physiologically active substances. 17. Thienoisoxazoles through nucleophile substitution].
Topics: Chemical Phenomena; Chemistry; Isoxazoles; Oxazoles; Thiophenes | 1988 |
5-( [aryl or aryloxy (or thio)]methyl)-3-(1H-imidazol-1-ylmethyl)-3- (2-thienyl)-2-methylisoxazolidine derivatives as novel antifungal agents.
Topics: Antifungal Agents; Chemical Phenomena; Chemistry; Fungi; Imidazoles; Isoxazoles; Microbial Sensitivity Tests; Molecular Conformation; Oxazoles; Thiophenes | 1988 |
[Thiophene as a structural element of physiologically active compounds. 16. Thienoisoxazoles by substitution at the oxime nitrogen].
Topics: Animals; Anticonvulsants; Chemical Phenomena; Chemistry; Isoxazoles; Mice; Oxazoles; Rats; Thiophenes | 1987 |
The analysis of combining sites of rabbit anti-benzylpenicilloyl antibodies.
Topics: Animals; Antibody Specificity; Antigen-Antibody Reactions; Benzene; Binding Sites, Antibody; Cattle; Chlorine; gamma-Globulins; Haptens; Humans; Kinetics; Oxazoles; Penicillin G; Rabbits; Structure-Activity Relationship; Thermodynamics; Thiophenes | 1972 |
Application of photoelectron spectrometry to pesticide analysis. Photoelectron spectra of five-membered heterocycles and related molecules.
Topics: Bridged-Ring Compounds; Cyclopentanes; Furans; Oxazoles; Pesticides; Photometry; Pyrazoles; Pyrroles; Spectrum Analysis; Thiophenes | 1970 |
Pteridines. 8. Some 2,4,7-triamino-6-heteroarylpteridines.
Topics: Chromatography, Paper; Furans; Hydrogen-Ion Concentration; Imidazoles; Oxazoles; Pteridines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Spectrum Analysis; Thiazoles; Thiophenes; Triazoles; Ultraviolet Rays | 1968 |
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Heparin; Lasers; Male; Mesenteric Arteries; Mesenteric Vascular Occlusion; Molsidomine; Oxazoles; Platelet Aggregation; Propionates; Pyrazoles; Pyrazolones; Rats; Rats, Inbred Strains; Sydnones; Thiophenes; Thrombosis; Ticlopidine | 1983 |
Selectivity of a series of clonidine-like drugs for alpha 1 and alpha 2 adrenoceptors in rat brain.
Topics: Aniline Compounds; Animals; Cerebral Cortex; Clonidine; Guanabenz; Guanfacine; Guanidines; Imidazoles; In Vitro Techniques; Indoramin; Naphazoline; Oxazoles; Phenylacetates; Prazosin; Rats; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Structure-Activity Relationship; Thiophenes; Toluidines | 1980 |
Synthesis and absolute configuration of a tinofedrine-oxazolidine derivative.
Topics: Models, Molecular; Molecular Conformation; Oxazoles; Thiophenes; X-Ray Diffraction | 1982 |
Time-dependent efficacy of antihypertensive agents in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Captopril; Circadian Rhythm; Clonidine; Felodipine; Heart Rate; Hypertension; Labetalol; Male; Metoprolol; Oxazoles; Prazosin; Propanolamines; Propranolol; Rats; Rats, Inbred SHR; Rilmenidine; Thiophenes | 1993 |
The chemistry of pseudomonic acid. Part 14. Synthesis and in vivo biological activity of heterocyclyl substituted oxazole derivatives.
Topics: Animals; Anti-Bacterial Agents; Furans; Humans; Isoxazoles; Mice; Mupirocin; Oxazoles; Pyrazoles; Pyridines; Sepsis; Staphylococcal Infections; Thiazoles; Thiophenes | 1995 |
Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Gastric Juice; Guanidines; Guinea Pigs; Helicobacter pylori; Histamine H2 Antagonists; In Vitro Techniques; Male; Microbial Sensitivity Tests; Myocardium; Oxazoles; Rats; Structure-Activity Relationship; Thiazoles; Thiophenes | 2002 |
Crystal structures of two potent nonamidine inhibitors bound to factor Xa.
Topics: Amidines; Anticoagulants; Crystallization; Crystallography, X-Ray; Factor Xa Inhibitors; Humans; Molecular Conformation; ortho-Aminobenzoates; Oxazoles; Serine Proteinase Inhibitors; Structure-Activity Relationship; Thiophenes | 2002 |
Synthesis and biological evaluation of five-membered heterocycles fused to cyclopenta[c]thiophene as new antitumor agents.
Topics: Animals; Antineoplastic Agents; Cyclopentanes; Drug Screening Assays, Antitumor; Heterocyclic Compounds; Humans; Indicators and Reagents; Mice; Neoplasm Transplantation; Oxazoles; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Transplantation, Heterologous | 2003 |
Synthesis of new bisaryl cyclopentathiophene and thienocyclopentoxazolidine derivatives as potential cytotoxic agents.
Topics: Antineoplastic Agents; Bromine; Cell Line, Tumor; Cross-Linking Reagents; Cyclopentanes; Drug Screening Assays, Antitumor; Humans; Hydrocarbons, Aromatic; Molecular Structure; Oxazoles; Thiophenes | 2007 |
Aryl triflates: useful coupling partners for the direct arylation of heteroaryl derivatives via Pd-catalyzed C-H activation-functionalization.
Topics: Catalysis; Furans; Mesylates; Oxazoles; Palladium; Thiazoles; Thiophenes | 2008 |
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes | 2009 |
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Topics: Alkanesulfonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Thiophenes | 2009 |
Protein kinase C{gamma} mediates regulation of proliferation by the serotonin 5-hydroxytryptamine receptor 2B.
Topics: Animals; Chromones; Coiled Bodies; Enzyme Inhibitors; Estrenes; Fibroblasts; Indoles; Macrocyclic Compounds; Mice; Mice, Inbred C57BL; Mice, Transgenic; Morpholines; Oxazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase C; Pyrrolidinones; Receptor, Serotonin, 5-HT2B; Thiophenes | 2009 |
Short and general procedure for synthesizing cis-1,2-fused 1,3-oxathiolan-, 1,3-oxaselenolan-, and 1,3-oxazolidin-2-imine carbohydrate derivatives.
Topics: Carbohydrates; Imines; Magnetic Resonance Spectroscopy; Molecular Structure; Oxazoles; Selenium Compounds; Thiophenes | 2010 |
Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk Factors; Thiophenes | 2010 |
Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Topics: Administration, Oral; Animals; Apolipoprotein A-I; Apolipoprotein A-II; Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Disease Models, Animal; Eating; Glycated Hemoglobin; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Macaca mulatta; Male; Metabolic Syndrome; Obesity; Oxazoles; PPAR alpha; PPAR gamma; Prediabetic State; Thiophenes; Time Factors; Triglycerides; Weight Loss | 2011 |
Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
Topics: Administration, Oral; Animals; Cell Line; Dose-Response Relationship, Drug; Hypoglycemic Agents; Inhibitory Concentration 50; Mice; Molecular Structure; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Binding; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Thiophenes | 2011 |
Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Topics: Amino Acid Sequence; Animals; Cell Line; Cricetinae; Fenofibrate; Ligands; Molecular Sequence Data; Oxazoles; Peptides; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes; Transcription, Genetic | 2012 |
Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
Topics: Alkanesulfonates; Cells, Cultured; Fenofibrate; Hepatocytes; Humans; Oxazoles; Phenylpropionates; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Thiophenes | 2012 |
Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
Topics: Animals; Blood Glucose; Cataract; Diabetic Nephropathies; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin; Islets of Langerhans; Male; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Thiophenes | 2013 |
Benzofuran-, benzothiophene-, indazole- and benzisoxazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1.
Topics: Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Enzyme Assays; Humans; Indazoles; NAD(P)H Dehydrogenase (Quinone); Oxazoles; Oxidation-Reduction; Quinones; Thiophenes | 2013 |
Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms.
Topics: Angiotensin-Converting Enzyme 2; Anthracenes; Benzamides; Blotting, Western; Cathepsin B; Cathepsin L; DNA Primers; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorometry; HEK293 Cells; Humans; Immunoprecipitation; Luciferases; Oxazoles; Peptidyl-Dipeptidase A; Piperazines; Real-Time Polymerase Chain Reaction; Severe acute respiratory syndrome-related coronavirus; Small Molecule Libraries; Thiophenes; Thiourea; Virus Internalization | 2013 |
The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Case-Control Studies; Cell Movement; Cell Proliferation; Cells, Cultured; Coronary Artery Disease; Disease Models, Animal; Endothelial Cells; Hindlimb; Humans; Ischemia; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Oxazoles; PPAR alpha; PPAR gamma; Signal Transduction; Stem Cells; Thiophenes | 2014 |
Cinchona alkaloid derivative-catalyzed enantioselective synthesis via a Mannich-type reaction and antifungal activity of β-amino esters bearing benzoheterocycle moieties.
Topics: Amino Acids; Antifungal Agents; Benzothiazoles; Catalysis; Cinchona Alkaloids; Esters; Fusarium; Microbial Sensitivity Tests; Oxazoles; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Thiourea | 2014 |
A cyclization-carbonylation-cyclization coupling reaction of (ortho-alkynyl phenyl) (methoxymethyl) sulfides with the palladium(II)-bisoxazoline catalyst.
Topics: Carbonates; Catalysis; Coordination Complexes; Cyclization; Ketones; Ligands; Oxazoles; Palladium; Sulfides; Thiophenes | 2014 |
Acute coronary syndromes: Aleglitazar trial findings reported.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Oxazoles; Thiophenes | 2014 |
Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
Topics: Animals; Aripiprazole; Boron Compounds; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; HSP90 Heat-Shock Proteins; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Nerve Growth Factor; Neurites; Oxazoles; PC12 Cells; Piperazines; Piperidines; Pyridines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin Agents; Thiophenes | 2015 |
Inhibition of eosinophil apoptosis by asthma-relevant cytokines from platelets.
Topics: Animals; Asthma, Aspirin-Induced; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Eosinophils; Humans; Oxazoles; Piperazines; Thiophenes | 2015 |
Palladium-Catalyzed Heteroarylation and Concomitant ortho-Alkylation of Aryl Iodides.
Topics: Alkylation; Catalysis; Hydrocarbons, Iodinated; Iodides; Molecular Structure; Organometallic Compounds; Oxazoles; Palladium; Thiazoles; Thiophenes | 2015 |
Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Chromans; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Fenofibrate; Gene Expression; Humans; K562 Cells; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rhodamine 123; Signal Transduction; Thiazolidinediones; Thiophenes; Troglitazone | 2015 |
Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cardiovascular Agents; Cell Survival; Diabetes Mellitus, Experimental; Heart; Humans; Male; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Oxazoles; PPAR alpha; PPAR gamma; Protective Agents; Signal Transduction; Thiophenes | 2016 |
Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Topics: Adipocytes; Adiponectin; Cell Line; Cell Movement; Cell Survival; Chemokine CCL2; Chemokine CXCL10; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Lipid Metabolism; Oxazoles; p38 Mitogen-Activated Protein Kinases; PPAR alpha; PPAR gamma; Thiophenes; Tumor Necrosis Factor-alpha | 2016 |
Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells.
Topics: Acyltransferases; Anilides; Animals; Blotting, Northern; Caco-2 Cells; Cell Line; Cell Line, Tumor; Chromatin Immunoprecipitation; Computational Biology; HT29 Cells; Humans; Kidney Tubules, Proximal; Liver; Mice; Oxazoles; PPAR alpha; Promoter Regions, Genetic; Pyrimidines; Rats; Real-Time Polymerase Chain Reaction; Rosiglitazone; Sulfones; Thiazoles; Thiazolidinediones; Thiophenes; Tyrosine | 2016 |
Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
Topics: Animals; Apoptosis; Caspase 3; Cell Survival; Cells, Cultured; Cytochromes c; Cytoprotection; Dose-Response Relationship, Drug; Genotype; Hyperglycemia; Hypoglycemic Agents; Mice, Knockout; Myocytes, Cardiac; Oxazoles; Oxidative Stress; Phenotype; PPAR alpha; PPAR gamma; RNA Interference; Signal Transduction; Thiophenes; Time Factors; Transfection | 2017 |
Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite.
Topics: Animals; Carcinogenicity Tests; Cricetinae; Humans; Macaca fascicularis; Mice; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Risk Assessment; Thiophenes; Toxicity Tests | 2017 |
Evaluation of analogues of furan-amidines as inhibitors of NQO2.
Topics: Amidines; Antimalarials; Enzyme Inhibitors; Furans; Imidazoles; Molecular Structure; Oxazoles; Oximes; Plasmodium falciparum; Quinone Reductases; Structure-Activity Relationship; Thiophenes | 2018 |
Beneficial Effects of the Peroxisome Proliferator-Activated Receptor α/γ Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension.
Topics: Animals; Caco-2 Cells; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Male; Neovascularization, Pathologic; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Splanchnic Circulation; Thiophenes | 2018 |
Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Mice; Oxazoles; PPAR alpha; PPAR gamma; Stroke; Thiophenes | 2019 |
Oleic acid-induced perilipin 5 expression and lipid droplets formation are regulated by the PI3K/PPARα pathway in HepG2 cells.
Topics: Azo Compounds; Chromones; Gene Expression Regulation; Hep G2 Cells; Humans; Imidazoles; Lipid Droplets; Morpholines; Oleic Acid; Oxazoles; Perilipin-5; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PPAR alpha; Pyridines; Staining and Labeling; Sulfones; Thiophenes; Tyrosine | 2019 |
A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase.
Topics: Animals; Antiviral Agents; Binding Sites; Drug Design; Enzyme Inhibitors; Gene Expression; Humans; Mice; Molecular Docking Simulation; Norovirus; Oxazoles; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Pyrimidines; RAW 264.7 Cells; RNA-Dependent RNA Polymerase; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Thiophenes; Viral Proteins; Virus Replication | 2019 |
Pharmacological Blockade of PPAR Isoforms Increases Conditioned Fear Responding in the Presence of Nociceptive Tone.
Topics: Analgesia; Anilides; Animals; Conditioning, Psychological; Extinction, Psychological; Fear; Formaldehyde; Freezing Reaction, Cataleptic; Gene Expression; Male; Nociceptive Pain; Oxazoles; PPAR alpha; PPAR delta; PPAR gamma; PPAR-beta; Rats; Rats, Sprague-Dawley; Sulfones; Thiophenes; Tyrosine | 2020 |
Chrysomya bezziana (Diptera: Calliphoridae) infestation in two Malaysian cats treated with oral lotilaner.
Topics: Animals; Calliphoridae; Cat Diseases; Cats; Larva; Male; Oxazoles; Screw Worm Infection; Thiophenes; Treatment Outcome | 2020 |
The molecular targets of ivermectin and lotilaner in the human louse Pediculus humanus humanus: New prospects for the treatment of pediculosis.
Topics: Animals; Antiparasitic Agents; Chloride Channels; Female; Humans; Ivermectin; Lice Infestations; Male; Oocytes; Oxazoles; Pediculus; Protein Subunits; Thiophenes; Toxicity Tests; Xenopus laevis | 2021 |
A randomized, controlled field study to assess the efficacy and safety of lotilaner flavored chewable tablets (Credelio™ CAT) in eliminating fleas in client-owned cats in the USA.
Topics: Administration, Oral; Animals; Cat Diseases; Cats; Ctenocephalides; Female; Flea Infestations; Hospitals, Animal; Insecticides; Male; Mastication; Ownership; Oxazoles; Pets; Random Allocation; Skin; Tablets; Thiophenes; Treatment Outcome; United States | 2021 |
Efficacy of lotilaner (Credelio™) against experimentally induced infestations of the adult cat flea, Ctenocephalides felis, and flea eggs following oral administration to cats.
Topics: Administration, Oral; Animals; Cat Diseases; Cats; Ctenocephalides; Female; Flea Infestations; Insecticides; Male; Ovum; Oxazoles; Random Allocation; Thiophenes | 2021 |
Effectiveness of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio
Topics: Administration, Oral; Ancylostoma; Ancylostomiasis; Animals; Anthelmintics; Dog Diseases; Dogs; Drug Combinations; Female; Intestinal Diseases, Parasitic; Larva; Macrolides; Male; Oxazoles; Parasite Egg Count; Random Allocation; Thiophenes; Treatment Outcome | 2021 |
Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio
Topics: Animals; Dog Diseases; Dogs; Drug Combinations; Europe; Feces; Female; Hospitals, Animal; Macrolides; Male; Nematoda; Nematode Infections; Oxazoles; Parasite Egg Count; Parasitic Diseases, Animal; Pets; Random Allocation; Thiophenes | 2021 |
Effectiveness of Credelio
Topics: Administration, Oral; Animals; Anthelmintics; Dog Diseases; Dogs; Drug Combinations; Female; Intestinal Diseases, Parasitic; Larva; Macrolides; Male; Mastication; Oxazoles; Random Allocation; Tablets; Thiophenes; Toxocara canis; Toxocariasis | 2021 |
Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio
Topics: Administration, Oral; Animals; Dirofilaria immitis; Dirofilariasis; Dog Diseases; Dogs; Drug Combinations; Female; Hospitals, Animal; Macrolides; Male; Mississippi; Ownership; Oxazoles; Thiophenes; Treatment Outcome; United States | 2021 |
Credelio® Plus: a novel oral endectocide for dogs.
Topics: Animals; Dog Diseases; Dogs; Macrolides; Oxazoles; Thiophenes | 2021 |
Early onset of pre-lethal effects of lotilaner (Credelio
Topics: Acaricides; Administration, Oral; Amblyomma; Animals; Dog Diseases; Dogs; Female; Male; Oxazoles; Random Allocation; Thiophenes; Tick Infestations; Time Factors | 2021 |
Effectiveness of lotilaner against ticks of the genus Amblyomma spp. in three naturally infested cane toads (Rhinella horribilis).
Topics: Administration, Oral; Amblyomma; Animals; Bufonidae; Oxazoles; Thiophenes; Tick Infestations | 2022 |
Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents.
Topics: Animals; Antifungal Agents; Aspergillus fumigatus; Candida albicans; Cryptococcus neoformans; Dose-Response Relationship, Drug; Drug Design; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Oxazoles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiophenes | 2022 |
Thiophene α-Chain-End-Functionalized Oligo(2-methyl-2-oxazoline) as Precursor Amphiphilic Macromonomer for Grafted Conjugated Oligomers/Polymers and as a Multifunctional Material with Relevant Properties for Biomedical Applications.
Topics: Micelles; Oxazoles; Polymers; Thiophenes; Water | 2022 |